Grand River Has Come a Long Way

TPDs

Low Dose, High Impact: Microdosing, Content Uniformity, and Precision Control in TPDs

David O’Connell

PCI Pharma Services

Lipase Risk

An Integrated Analytical Approach to Lipase Risk Management in Biologics Development

Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun

Samsung Biologics

Partner Selection

How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?

Pharma's Almanac

Chinese Biopharma

Pharmaceutical Innovation in China Takes Center Stage

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Potency Assurance

Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development

David Alvaro, Ph.D.

Pharma's Almanac

Supply Chain

Supply Chain Resilience in 2026: Any Progress?

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Prevention

Preventive Therapeutics Beyond Vaccines

David Alvaro, Ph.D.

Pharma's Almanac

Masked Antibody

Expanding the Oncology Therapeutic Window Through Masked Antibody Technology

Sean McCarthy, Ph.D; David Alvaro, Ph.D.

CytomX Therapeutics

AOCs

Antibody–Oligonucleotide Conjugates Clinical Manufacturing — A New Paradigm Shift of Bio-Conjugates for Therapeutics

Muctarr Sesay, Ph.D.; Natalia Bourguignon, Ph.D.

GBI Biomanufacturing